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PURPOSE. The purpose of this study was to evaluate ciprofloxacin-releasing silicone hydrogel
contact lens materials in vitro and in vivo for the treatment of microbial keratitis.
METHODS. Model silicone hydrogel contact lens materials were manufactured using a
molecular imprinting technique to modify ciprofloxacin release kinetics. Various contact
lens properties, including light transmission and surface wettability, were determined, and the
in vitro ciprofloxacin release kinetics elucidated using fluorescence spectrophotometry. The
materials then were evaluated for their ability to inhibit Pseudomonas aeruginosa growth in
vitro and in an in vivo rabbit model of microbial keratitis.
RESULTS. Synthesized lenses had similar material properties to commercial contact lens
materials. There was a decrease in light transmission in the shorter wavelengths due to
incorporation of the antibiotic, but over 80% light transmission between 400 and 700 nm.
Modified materials released for more than 8 hours, significantly longer than unmodified
controls (P < 0.05). In vivo, there was no statistically significant difference between the
number of colony-forming units (CFU) recovered from corneas treated with eye drops and
those treated with one of two modified contact lenses (P > 0.05), which is significantly less
than corneas treated with unmodified control lenses or those that received no treatment at all
(P < 0.05).
CONCLUSIONS. These novel contact lenses designed for the extended release of ciprofloxacin
may be beneficial to supplement or augment future treatments of sight-threatening microbial
keratitis.
Keywords: contact lens, microbial keratitis, drug delivery, molecular imprinting, ciprofloxacin
Microbial keratitis (MK), an infection of the cornea bypathogenic microorganisms, represents a true ocular
emergency. Unless immediate treatment is initiated with
appropriate antimicrobial agents, the probability of retaining
normal vision is unlikely.1 Epidemiological studies have
identified certain risk factors for the development of MK,
including male sex, younger age, overnight wear of contact
lenses (CLs), smoking, poor hygiene, and internet supply of
lenses.2–4 Unfortunately, even with all of the advances in our
understanding of MK and implementation of solutions to lower
modifiable risk, the incidence of the disease has remained
largely unchanged.5 Contemporary treatment of patients with
MK involves the frequent use of topical antibiotic agents, often
fortified by a compounding pharmacy.6 In the early stages of
treatment, drop instillation as frequently as every 15 minutes is
common to quickly saturate the cornea to therapeutic
antibiotic levels. Even with these frequent dosing schedules,
practical considerations on the pharmacokinetics of eye drops
suggests that the therapeutic windows are reached only for
relatively short periods of time, interspersed between times of
therapeutic overdose and underdose.7 Indeed, measurements
and modeling suggest that at most only 5% to 10% of an instilled
eye drop ultimately exerts therapeutic action, with the
remainder flushed away and absorbed systemically.8 This is
disadvantageous economically and therapeutically, as useful
molecules are lost without exerting a therapeutic effect, and
systemically absorbed agents have the potential to cause side
effects. Adherence to strict and frequent treatment regimens
for the management of MK is understandably difficult for
outpatients; thus, management often requires hospitalization,
costing the health care system and individual significant
amounts of time and money.9 Economic analysis of the MK
costs in Australia suggests that each case costs upwards of AUD
$10,000.10 Given these therapeutic, practical, and economic
challenges, development of alternative MK therapies are
warranted and may prove to be beneficial.
Even though CLs are risk factors for developing MK, the use
of CLs as vehicles to deliver therapeutics to the eye has been
suggested and is not a recent idea. Using hydrogels, such as CLs,
as a reservoir for a drug during the treatment of anterior
segment disease was proposed as early as 1965 by Sedla´cek,11
and has received renewed research interest of late.11,12 The
appeals of a CL drug delivery device are numerous. The
materials have a proven track record of biocompatibility and
patient and practitioner acceptance.13 Modern manufacturing
methods have driven the unit cost of each lens to affordable
levels. If CLs are used in a drug delivery application, they also
can simultaneously correct for refractive error, allowing for
continued clarity of vision by the patient undergoing treatment.
The oxygen permeability of the lenses also have increased
significantly with the introduction of silicone hydrogel materi-
als in the late 1990s, allowing for potentially extended or
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overnight treatments with CLs without fear of hypoxic
complications.14 There also exists evidence that combination
CL and drug delivery devices would be well accepted by eye
care practitioners. In surveys of practicing optometrists and
ophthalmologists in North America, a large proportion of
practitioners surveyed used CLs as bandages when indicated,
and crucially, concurrently also prescribed topical medications,
such as antibiotics and anti-inflammatories, and would be
willing to accept a lens that did both simultaneously.15
The contemporary challenge in the development of a
successful drug delivery CL has been the drug release kinetics.
Not surprisingly, off-the-shelf commercial CL materials show
less than ideal drug release characteristics. The majority of
lenses examined showed very rapid release kinetics when
tested in vitro. Antibiotics (ciprofloxacin),16 anti-inflammato-
ries (ketorolac, dexamethasone),17,18 and antiallergy agents
(ketotifen fumarate)19 have all been tested, and while
differences in the absolute amount of the drug being released
between commercial lens types are seen, the release time
typically is limited to one or two hours. Given this restriction,
the focus of research has centered on modifying, extending,
and controlling release times. Numerous techniques have been
investigated. For example, a group has investigated modifica-
tion of commercial materials through the incorporation of a
Vitamin E coating, to serve as an additional diffusion barrier for
drug migration. This technique allowed for extension of release
times from several minutes to several hours in vitro, and has
been used to investigate release of timolol, an antiglaucoma
treatment.20 The authors were able to demonstrate improved
IOP control using the experimental CL system in comparison
with eye drops in a glaucomatous dog model.21 A novel design
involving a drug-impregnated film sandwiched between two
hydrogel pieces also has been investigated for delivery of
antibiotics and antifungals.22,23 Use of such a system showed a
significant increase in the amount of drug released and
favorable release kinetics in vitro. Unfortunately, the design
was limited by the optical properties of the lens, as the film
used as the drug reservoir was opaque, necessitating that the
lens require a small, 3-mm pupil cut in the middle of the film to
be used for vision, a design that is unlikely to resonate with eye
care practitioners or patients.
Molecular imprinting is a strategy that has been derived
from work in chromatography. Originally, polymers created by
this technique were used to preferentially remove certain
components from solutions.24 In this technique, the molecule
of interest ultimately to be released is dissolved in the
prepolymerization mixture.25 Inclusion of a separate small
molecule, denoted as the functional monomer, to specifically
interact with the molecule of interest through noncovalent
interactions, such as hydrogen bonding, creates shape-specific
and functional group-specific complexes deemed ‘‘cavities’’ or
‘‘molecular memory’’ within the final polymerized product.26
This ‘‘molecular memory’’ can significantly slow the movement
of the drug of interest from the material; thus, extending drug
release times.12 Previous work has demonstrated that selection
of the appropriate functional monomer and the ratio of the
functional monomer to the template, are the most crucial
aspects in generating materials with desired extended drug
release properties.27 This technique has been used successfully
to increase the drug release times observed in vitro for
antibiotics, anti-inflammatories, antiglaucoma, and antiallergy
medications.28–35
In this current study, novel silicone hydrogel CLs were
created using a molecular imprinting technique to increase the
release times of the fluoroquinolone antibiotic ciprofloxacin.
The molecule acrylic acid had been shown previously to be a
useful functional monomer to increase fluoroquinolone release
times.28,34 The materials were tested for their CL properties, in
vitro drug release characteristics, and sustained antibacterial
activity in an in vivo rabbit model of MK.
MATERIALS AND METHODS
Reagents
2-Hydroxylethlymethacrylate (HEMA), methacryloxy propyl
tris (trimethylsiloxy) silane (TRIS), ethylene glycol dimethacry-
late (EGDMA), acrylic acid, ciprofloxacin-HCL, Irgacure-1173,
polyvinylpyrrolidone (PVP), phosphate buffered saline (PBS),
and chloroform were purchased from Sigma-Aldrich (Oakville,
ON, Canada). Nutrient Agar was purchased from Sigma-Aldrich
PTY (Sydney, Australia). The BBL cation adjusted Mueller-
Hinton II Broth and Dey/Engley Neutralizing Broth were
purchased from BD Australia (North Ryde, New South Wales,
Australia). Polypropelene CL molds were kindly donated from
Alcon Vision Care (formerly CIBA Vision, Fort Worth, TX, USA).
The polymerizer inhibitor 4-methoxyphenol (MEHQ) was
removed from the HEMA and TRIS monomers by passing
through a column of Aldrich inhibitor removers. All other
reagents were used as received.
Molecular Imprinted CL Synthesis
Filtered HEMA (3.6 g) was mixed with 0.4 g of filtered TRIS, 0.1
g of EGDMA, and 0.3 g of PVP. To this, a 1 mL acrylic acid and
ciprofloxacin solution dissolved in chloroform was added so
that the final concentration of acrylic acid within the mixture
was 100 mM. Control lenses were created by omitting the
ciprofloxacin in the acrylic acid solution. Various ratios of
acrylic acid to ciprofloxacin solutions were made, ranging
from 4:1 moles of acrylic acid:ciprofloxacin, 8:1 moles acrylic
acid:ciprofloxacin, and 16:1 moles acrylic acid:ciprofloxacin
(hereby denoted as lens ‘‘4:1 imprinted,’’ ‘‘8:1 imprinted,’’ and
‘‘16:1 imprinted,’’ respectively). Isopropanol (1 mL) was added
as a diluent, and 0.04 g of the photoinitiator Irgacure 1173
added, and the solution mixed for five minutes at room
temperature. Then, 100 lL of the solution were injected into
plastic molds, and cured for five minutes using a UV oven
(Dymax Silver EC Series UV Light Curing Flood Lamp System;
Ellsworth Adhesives Canada, Stoney Creek, Ontario). The
cured lenses were removed from the molds, and lenses rinsed
daily with acetate buffer (pH 4.0) until no ciprofloxacin could
be detected by spectrophotometry. The lenses then were
soaked in isopropanol for 1 day to remove any leftover
monomers, before being rinsed and stored in PBS.
Determination of Material Properties – Water
Content, Wet and Dry Weight, Light Transmission,
Center Thickness, Surface Wettability
The water content, and wet and dry weight of lenses were
determined using the gravimetric method (Sartorius MA 100;
Sartorius Canada, Inc., Mississauga, Ontario), where the change
in weight as the lens was heated to 1058C over the course of 7
minutes was correlated to the water content of the lens. The
center thickness of a fully hydrated lens was measured using a
CL thickness gauge (Vigor Contact Lens Thickness Gauge;
Vigor Optical, Carlstadt, NJ, USA). To determine the light
transmission, individual lenses and 1 mL of PBS were placed
into wells of a 24-well plate, and a wavelength scan from 300 to
750 nm was conducted using a plate reader (Spectramax M5
Microplate reader; Molecular Devices, Sunnyvale, CA, USA).
The advancing contact angle, a measure of the surface
Ciprofloxacin-Releasing Contact Lenses IOVS j August 2014 j Vol. 55 j No. 8 j 4897
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/932996/ on 03/07/2017
wettability, was determined using the sessile drop method
employing the Optical Contact Analyzer (OCA; Dataphysics
Instruments GmbH, Filderstadt, Germany). A fully hydrated
lens was removed from the PBS soaking solution, and the
surface dried on lens paper for 20 seconds before being placed
on a custom-designed lens holder. Then, 5 lL of high
performance liquid chromatography (HPLC) water was dis-
pensed from a syringe, and an image of the contact of the
water droplet with the lens surface after settling captured
using a high speed camera.36,37 The contact angle between the
settled drop and the lens surface was analyzed using custom
software (SCA 20 software, Version 2.04, Build 4; Dataphysics
Instruments GmbH).
In Vitro Testing of Ciprofloxacin Release
Prepared lenses were removed from PBS and placed into 4 mL
of a 0.3% (3000 lg/mL) ciprofloxacin solution prepared in
acetate buffer (pH 4.0). The lenses were autoclaved, and
allowed to take up ciprofloxacin from the solution for one
week. After one week, the amount of ciprofloxacin loaded
into the lenses was determined using fluorescence spectro-
photometry in comparison with previously generated stan-
dard curves (excitation wavelength 274 nm, emission 419
nm). The lenses then were removed and the surface briefly
dried on Lens Paper (VWR Scientific Products, Westchester,
PA, USA) before being placed into 2 mL of PBS. Then, 100 lL
of PBS was removed at set intervals over the course of 24
hours, and the concentration of ciprofloxacin determined by
spectrophotometry. After 24 hours, the lenses were removed,
the surface briefly dried on lens paper, and placed into a
second vial with 2 mL of fresh PBS, and the time course
release was again monitored for another 24 hours. This
process was repeated one additional time for a third day to
generate release curves.
Bacterial Strain and Growth, Minimum Inhibitory
Concentration (MIC) Determination
Pseudomonas aeruginosa strain 6294, a bacterial strain
previously isolated in the United States from a human case of
MK,38 was streaked on nutrient agar plates from808C frozen
stocks and incubated at 348C for 18 hours. A single colony was
picked and grown overnight in Mueller-Hinton Broth before
being centrifuged, rinsed in PBS, and resuspended in PBS to an
optical density of 0.1 at 660 nm (approximately 13108 colony-
forming units [CFU]/mL). The MIC of the test organism was
determined using the broth microdilution method.39 P.
aeruginosa strain 6294 (53 104 CFU) was added to each well
of a 96-well plate, with each well containing a doubling
dilution concentration of ciprofloxacin in Mueller-Hinton
Broth. The plate was incubated overnight, and the turbidity
of the solution in individual wells used to determine the
minimum concentration of the antibiotic that prevents
bacterial growth.
In Vitro Testing of Antimicrobial Activity
Test lenses were removed from the loading solution and briefly
dipped in PBS before being added to 2 mL of Mueller-Hinton
Broth seeded with 1 3 108 CFU/mL P. aeruginosa. Then, 100
lL were sampled hourly into neutralizing broth, and serial
dilutions plated on nutrient agar plates. The plates were
incubated at 348C for 18 hours before counting for CFU. The
lenses were removed from solution after 24 and 48 hours,
briefly dipped in PBS, and placed into fresh Mueller-Hinton
bacterial solutions, and the procedure repeated.
In Vivo Testing of Antimicrobial Activity – Rabbit
Scratch Model of MK
All animal procedures were approved by the executive of the
animal care and ethics committee at the University of New
South Wales, and performed in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research. New Zealand White rabbits (4 kg) were sourced
from S&J Hurrell in Sydney, New South Wales, Australia. After
acclimatization for 1 week, the nictitating membrane was
removed surgically from both eyes under general anesthesia.
Recovery was allowed for a minimum of one week, at which
time two 5-mm central corneal scratches on one eye were
induced using a 23-gauge needle under general anesthesia, and
20 lL of the P. aeruginosa strain 6294 solution placed on the
eye (approximately 2 3 106 CFU). The eyes were held closed
for 2 minutes, after which the rabbit was allowed to recover
from the anesthetic before being returned to the pen. Pain
control was achieved through subcutaneous injection of 0.02
mg/kg buprenorphine every 12 hours. At 16 hours after the
scratch and bacterial introduction, the rabbits were assigned
randomly to one of three intervention groups: intervention by
hourly instillation of 3000 lg/mL ciprofloxacin drops for 8
hours, intervention by one of three types of CLs (control, 4:1
imprinted, and 8:1 imprinted) loaded in 30 lg/mL ciproflox-
acin solution for 8 hours, or no intervention for 8 hours (three
rabbits per treatment condition). The animals were euthanized
by lethal injection of 1 mL of sodium pentobarbital intrave-
nously 24 hours after scratch, and the cornea excised. The
cornea was homogenized in neutralizing broth, and serial
dilutions of the homogenate plated on nutrient agar for 18
hours at 348C before CFU were counted.
Statistics
All statistics were performed using STATISTICA Version 7
(StatSoft, Tulsa, OK, USA). Analysis of in vitro release curves
and bacterial growth curves was done using a repeated
measures ANOVA, with lens type as a categorical factor, time
as a within effects factor, and lg/g dry weight ciprofloxacin
released or CFU as a dependent factor. Comparison of bacteria
recovered from rabbit corneas or material properties was done
using a 1-way ANOVA, with lens type as a categorical factor,
and the measured property as a dependent factor. Post hoc
Tukey tests were used as necessary. A P value of less than 0.05
was deemed to be statistically significant.
RESULTS
Material Properties
The water content, wet and dry weight, center thickness, and
advancing contact angle are summarized in Table 1.
There was no statistically significant difference in the wet
weight and center thicknesses of the lenses. The 4:1 imprinted
lenses were found to have dry weights statistically different
than the control and 8:1 imprinted lens (P < 0.05). The 4:1
imprinted lens was statistically significantly different than all
the other lenses in terms of water content (P < 0.05). All the
lenses were statistically different when compared to each other
with respect to contact angle (P < 0.001).
The light transmission of the four different lens types tested
is shown in Figure 1. Increasing the amount of ciprofloxacin
into the lens material led to increased yellow coloration of the
lens, and, thus, greater loss of light transmission in the shorter
wavelengths.
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In Vitro Testing of Ciprofloxacin Release
After autoclaving and allowing uptake of ciprofloxacin from
the loading solution for one week, the amount of ciprofloxacin
taken into each lens type is presented in Table 2. There was no
statistically significant difference between the amounts taken
up by the different lenses.
The in vitro release curves over the course of three days and
three releasing solutions are presented in Figures 2A through
2C. On the first release day, the control material reached a
plateau concentration after three hours, while the imprinted
materials released ciprofloxacin for five hours or more. The
plateau concentration of the control material was higher than
the imprinted materials, although this difference was not
statistically significant (P > 0.05). On the second release day in
the second release solution, the control and imprinted
materials reached a plateau concentration after four hours
and there were no statistically significant differences between
them. In the third release medium on the third day, the control
material reached a plateau concentration after a mere two
hours, while the 4:1 and 8:1 imprinted materials continued to
release for over eight hours. The plateau concentration
reached by the 4:1 and 8:1 imprinted materials also were
statistically different than the concentration reached by the
control (P < 0.05). The plateau concentration reached by the
least imprinted material, the 16:1 lens, was not statistically
different than the control.
In Vitro Antibacterial Assays
The as tested MIC of the P. aeruginosa strain 6294 was 0.4 lg/
mL. All lenses loaded with 0.3% ciprofloxacin were able to
inhibit the growth of bacteria completely for the first two days,
suggesting that inhibitory amounts of the antibiotic were being
released from the lenses. The ability of the lenses to inhibit the
growth of P. aeruginosa strain 6294 in Mueller Hinton Broth
on the third day is presented in Figure 3. There was an initial
decrease in concentration of bacteria as the final reserves of
ciprofloxacin were released from the lenses. The rate at which
the number of viable bacteria were decreasing is indicative of
concentration of antibiotic in solution, suggesting that the
control lens initially reaches a higher concentration than the
two imprinted lenses, which correlates to the released data
seen in Figure 2C. As complete inhibitory concentrations were
not reached by any of the lenses, by the 8-hour time point the
bacteria population began to rebound. There was a statistically
significant decrease in the number of bacteria from the
beginning to the end of the monitoring period for all three
lenses tested (P < 0.05). The differences between the lenses,
however, was not statistically significant (P > 0.05).
In Vivo Model of MK
Corneas scratched and exposed to P. aeruginosa strain 6294
began to show an infection response after 16 hours,
characterized by development of infiltrates, discharge, and
redness as shown in Figure 4B. Left untreated, the severity of
the infection increased dramatically over the next 8 hours
before euthanasia of the rabbit (Fig. 4C). Treatment interven-
tion with a modified CL at the 16-hour point partially resolved
the infiltrate or discharge by the 24-hour point (Fig. 4D).
The number of CFU recovered from excised and homoge-
nized infected corneas are presented in Figure 5. Left
untreated, approximately 106 CFU per cornea were recovered,
while treatment with hourly instillation of ciprofloxacin eye
drops led to complete sterilization and lack of any recoverable
bacteria from the cornea after only 8 hours. Treatment with
lenses soaked in only 30 lg/mL ciprofloxacin solutions (100
times less than the clinical drops) led to differences in bacterial
recovery. The number of bacteria recovered from corneas
treated with the control (i.e., no molecular imprinting) lenses
that had been soaked in ciprofloxacin was not significantly
FIGURE 1. Percentage light transmission curves. Control ( ), 4:1
imprinted ( ), 8:1 imprinted ( ), and 16:1 imprinted lenses ( ).
Increased incorporation of ciprofloxacin into the material leads to
increased yellow coloration of the lens, and a decrease in transmission
in the shorter wavelengths. Symbols represent averages 6 SD of 3
lenses.












Control 0.027 (0.004) 0.016 (0.003) 63 (14) 42.3 (4.5) 94.6 (1.5)
4:1 imprinted 0.029 (0.004) 0.019 (0.003) 64 (15) 36.2 (3.4) 77.4 (2.0)
8:1 imprinted 0.028 (0.006) 0.017 (0.004) 62 (19) 43.3 (3.0) 81.5 (1.3)
16:1 imprinted 0.028 (0.005) 0.016 (0.002) 61 (19) 41.7 (3.0) 89.2 (2.0)
All values are presented as averages (SD) of a minimum of four lenses. The imprinted lenses are denoted by the ratio of the moles of the
functional monomer acrylic acid to the moles of the template ciprofloxacin.
TABLE 2. Uptake of Ciprofloxacin Into Each of the Four Tested Lenses
Lens Type Ciprofloxacin Loaded, lg/lens, Mean (SD)
Control 1383 (144)
4:1 imprinted 1509 (291)
8:1 imprinted 1133 (264)
16:1 imprinted 1234 (295)
All values are presented as averages (SD) of a minimum of three
lenses.
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different than that of the nontreated control lenses (P > 0.05).
However, there is a significant reduction in the number of
recoverable bacteria from the corneas treated with the slow
release, molecularly-imprinted lenses (P < 0.05 when com-
pared to untreated control or untreated corneas). Many of the
corneas treated with the imprinted lenses were rendered
sterile through treatment, and overall no statistically significant
difference was found in the number of bacteria recovered from
those corneas and corneas treated with antibiotic eye drops (P
> 0.05).
DISCUSSION
The challenge in the development of CL drug delivery devices
remains the relevant drug release kinetics. Previous investiga-
tions into drug release from commercially available materials
demonstrated less than clinically useful drug release times (Ref.
40 and Karlgard C, et al. IOVS 2001;42:ARVO E-Abstract 592),
prompting the need for custom design lenses to be developed.
As seen from the drug release curves presented in Figure 2, by
using a molecular imprinting technique the ciprofloxacin
release profiles from CL materials were significantly altered. By
incorporating acrylic acid as a functional monomer within the
prepolymerization mixture in various ratios to ciprofloxacin,
materials were modified to release the antibiotic at various
rates, with a ratio of 4:1 functional monomer-to-template
molecule showing the greatest extension of release times. The
influence of the ratio of functional monomer to the template
on the efficiency of molecular imprinting has been presented
in the literature.41 Away from the optimum monomer-to-
template ratio, cavities created within the polymerization
structure will be inadequately or inefficiently created, and,
thus, shift the equilibrium toward disassociation and release of
the template, leading to faster release times when release
studies are performed in vitro.41 That the 4:1 ratio was shown
to be the most effective in slowing the release of ciprofloxacin
is not surprising, as the ratio had been demonstrated
FIGURE 2. In vitro ciprofloxacin release. Control ( ), 4:1 imprinted
( ), 8:1 imprinted ( ), and 16:1 imprinted lenses ( ) on Day 1 (A),
Day 2 (B), and Day 3 (C) after loading in a 0.3% ciprofloxacin solution
for 1 week. Symbols represent averages 6 SD of at least 4 lenses.
FIGURE 3. P. aeruginosa strain 6294 growth curves in presence of
ciprofloxacin releasing CLs. No viable bacteria were recovered from
the first two growth media on the first 2 days, as sufficient antibiotic
concentrations were reached in solution. The presented curves are
from the third bacterial solution on the third day, after a significant
amount of antibiotic was already released from the lenses. As inhibitory
concentrations were not reached, by the 8-hour time point the bacteria
numbers are beginning to recover and growth is beginning to increase.
Control ( ), 4:1 imprinted ( ), 8:1 imprinted ( ). Note exponential
scale.
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previously as most effective in experiments with molecular
imprinting and norfloxacin, a first generation fluoroquino-
lone.28 Through use of isothermal titration calorimetry, a
saturation in the binding of norfloxacin within the hydrogels at
a functional monomer-to-template ratio of 4:1 was observed,
and, thus, would be the ratio predicted to most perfectly create
the imprinted cavities and most prolong release times.28 This
prediction was demonstrated by the norfloxacin release data,
as ratios above or below 4:1 did not as effectively control
norfloxacin release.28 This experiment was an improvement to
previous in vitro experiments34 in that the releasing medium
was changed on a daily basis to better simulate the changing
concentration gradients that are likely to be seen if these
materials were placed on the eye. On the initial day, the
unmodified control lenses released a very high concentration
of drug, while the modified materials released for longer
periods, but reached lower final concentrations. As the release
medium solutions were changed, the advantage of the
molecular-imprinted materials began be more apparent. The
control material continued to release extremely rapidly, and
reached lower plateaus than the modified materials. This was
best exemplified by the data from the third releasing medium
on the third day, when the control material reached a fast
plateau of ciprofloxacin concentration within 2 hours, while
the 4:1 material continued to release for more than 8 hours,
and reached a significantly higher concentration in solution.
In vitro testing of the antibacterial activity of the test
materials served as a complement to the release of ciproflox-
acin in solution. Here, the differences in the recovered bacteria
FIGURE 4. Rabbit model of MK. (A) Cornea appearance before corneal scratching and bacteria introduction. (B) Cornea appearance 16 hours after
scratch, showing infiltrate, redness, and discharge. (C) Cornea appearance 24 hours after bacteria introduction without treatment showing a large
increase in size and severity of the MK. (D) Cornea treated with experimental CL for 8 hours 16 hours after bacteria introduction.
FIGURE 5. Bacteria recovered from excised, homogenized corneas.
The bacteria were recovered 24 hours after corneal scratch and
introduction of P. aeruginosa strain 6294, and 8 hours of different
treatment conditions. Corneas treated with drops had 10 lL of a 3000
lg/mL ciprofloxacin solution instilled hourly. Lenses used in the
treatment were presoaked and autoclaved in a 30 lg/mL solution of
ciprofloxacin. The numbers of bacteria recovered from the no
treatment and control lens treatments were significantly different than
those treated with ciprofloxacin eye drops or 4:1 or 8:1 imprinted
lenses (P < 0.05, n ¼ 3 for each treatment group). Note exponential
scale.
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were seen as a surrogate of the amount of ciprofloxacin
released. The test organism, P. aeruginosa strain 6294, is
ciprofloxacin-sensitive, with a MIC of 0.4 lg/mL. The growth
of the bacteria within the media is a function of several factors
– not only the concentration of ciprofloxacin within the
solution, but also the initial seeding concentration of bacteria,
the growth phase of the bacteria, and the availability of
resources, including nutrients and oxygen.42–44 The plotted
growth curves in Figure 3 reflect all of these factors
simultaneously. Several conclusions can be reached by
considering the growth of bacteria in the presence of these
lenses. First, each of the lenses were initially inhibiting the
growth of the bacteria, presumably due to release of the
antibiotic. Second, inhibition of growth by these lenses waned
over time. By the 8-hour mark, the bacterial population
stabilized or started to grow as the limited amount of
ciprofloxacin released from the lenses was exhausted or
insufficient to prevent multiplication, leaving bacterial growth
limited only by available resources. Third, while the differences
between the different lenses were not statistically significant,
examination of the different growth curves can be suggestive
of the effect of imprinting. The rate at which the population
growth was reduced by the lenses is reflective of the
concentration of the antibiotic in the solution. The control
lens, as previously demonstrated, released the majority of the
available ciprofloxacin very quickly, and reached higher
concentrations of antibiotic in solution faster than the two
slow release materials (Fig. 2C). Thus, the decrease in bacterial
concentration from systems treated with the control material
are expected to be faster than when treated with the two slow
release lenses, which is what is seen (Fig. 3). Thus, within a
closed, fixed in vitro solution, the control lens released
ciprofloxacin, which reached a high concentration quickly
and can be considered to be a superior lens used to control
bacterial growth.
In vitro testing of antibacterial activity, unfortunately, is an
inadequate model for in vivo applications. In the controlled,
closed system of a test tube or vial, the bacteria were exposed
to all of the antibiotic released from the experimental
materials, which would kill the bacteria cells. This was
regardless of the rate at which the antibiotic was being
released. This is in contrast to what occurs when antibiotic
drops or lenses are placed on the ocular surface, where
pharmacokinetic factors, including tear production and drain-
age, epithelial/corneal penetration, and drug metabolism are
significant factors in the amount of drug exerting an effect. If
the eye was a closed system, then the fast burst release from a
control lens could be advantageous and quickly raise drug
concentrations to effective levels. Unfortunately, because of
tear drainage and corneal cellular barriers, it is likely that much
of the antibiotic released in such a burst fashion will very
quickly be cleared from the ocular surface, limiting their
usefulness, which is why frequent dosing with eye drops is
necessary. In contrast, with a sustained release CL supplying
the antibiotic, a continual replenishment of the antibiotic is
possible. A fast rise to a high concentration is less likely, but
over time there is greater potential for therapeutic concentra-
tions to be reached, and more importantly, for them to be
sustained over a longer period of time. This is exemplified by
the in vivo results seen in Figure 5. Even with the superior
performance of the control lens (i.e., normal lenses soaked in
ciprofloxacin) against the bacteria in vitro, this superiority did
not translate in the in vivo rabbit model. The control lens did
not appreciably impact the number of recoverable bacteria
compared to no treatment, presumably because all of the
antibiotic was released at once, and any of the antibiotic not
absorbed was quickly drained away. In contrast, the two
imprinted lenses performed significantly better in reducing the
number of recoverable bacteria, as the reserves of ciproflox-
acin were released slowly over time and could replenish lost
drug that was drained away from the surface.
If the field of CL drug delivery is to continue and eventually
be accepted by practitioners and patients alike, the wearer
experience must be similar to regular CLs on the market. The
optical transmission in the visible range must be acceptable for
wear in day-to-day life, the water content and wettability must
remain within a certain narrow set of parameters to ensure
acceptable comfort during wear, and the amount of oxygen
being transmitted must be adequate to prevent complications.
As shown from the results of our experimental lenses, while
not surface-treated, they had acceptable wettability measures
in line with other nonsurface-treated silicone hydrogels that
incorporate an internal wetting agent, such as polyvinylpyrrol-
idone.45 The light transmission in the visible range is
acceptable, other than slight tinting of the lenses due to
ciprofloxacin drug incorporation causing a mild yellow
coloration. The center thickness and water contents also were
in line with commercial CLs. The incorporation of silicone
monomers into the material will allow for superior oxygen
transmission properties. Between the lenses, there were some
significant differences in water content and advancing contact
angle. The lenses that incorporated the greatest amount of
ciprofloxacin in the imprinting process, the 4:1 imprinted
lenses, also had the lowest water content. There also were
significant differences in the advancing contact angle, with a
trend toward lower contact angles as more ciprofloxacin was
used. Considering that the only difference in the synthesis of all
of the lenses is the amount of ciprofloxacin added, it can be
surmised that this difference in water content and advancing
contact angle is due to irreversible binding of some ciproflox-
acin within the materials during synthesis. The continued
yellow coloration of the CLs that had ciprofloxacin incorpo-
ration during the molecular imprinting process would lend
credence to this theory. The permanently-bound ciprofloxacin
is not expected to have had a significant effect on the
ciprofloxacin release characteristics from these lenses.
In this study, the ultimate test of the effectiveness of the
modified CL drug delivery device was performance in an in
vivo model of MK in New Zealand White rabbits. The use of
rabbits as a model for MK is well known, as they have an
adequate eye size to allow for CL wear.46 The methods and
selection of bacteria for infection also are critical. Classically, to
achieve infections of the cornea, animal models of keratitis
have required either passing of a silk suture soaked in a
bacterial solution into the corneal stroma or direct injection
into the corneal stroma of a bacterial solution to get a
consistent and repeatable keratitis response.46 The method
chosen in this study involved the creation of a superficial
scratch through the epithelium of the rabbit cornea before
exposure to a bacterial solution. This method mimicked to
some extent the CL rabbit model of Hume et al.,47 but without
the need to add spermidine.47 Usage of a highly virulent strain
of bacteria, P. aeruginosa strain 6294 allowed for consistent
keratitis responses to be seen under these experimental
conditions. The timing of the treatment also was carefully
chosen for two separate reasons. A total of 16 hours was
allowed to pass so that the MK response could be seen. It also
was chosen to mimic a more real-world situation, where a
patient may be reluctant to seek treatment after the initial
insult, and rather chooses to delay medical attention until the
condition and symptoms had significantly worsened. We were
limited ethically to an experiment of no more than 24 hours to
prevent significant pain, suffering, and distress to the
experimental animals. As is evident by the data (Fig. 5),
corneas treated with ciprofloxacin eye drops were rendered
sterile after only the short 8-hour treatment time frame.
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Indeed, this also was seen in treatment trials with the
molecularly imprinted CLs, as 2 of the 3 corneas in both of
the modified lens trials also were rendered sterile. However,
the clinical picture at this time does not reflect the sterility of
the cornea as all eyes at the 24-hour time point regardless of
treatment type continued to show significant infiltrates,
redness, edema, and discharge, although the severity varied
between the different treatment conditions. If the study could
have continued for longer, an alternative, more clinically
relevant outcome measure to recoverable bacteria could have
been used, such as time to resolution of the infiltrate and/or re-
epithelialization of the corneal surface. The sterility of the
corneas also is in contrast to what often is seen in the
experimental trials of novel antibiotic drops. For example, in a
recent trial testing the efficacy of a new fluoroquinolone
antibiotic drop, treatment with the new antibiotic (and other
commercially available antibiotics) did not completely sterilize
the cornea, rather it merely significantly impacted the number
of bacteria recovered compared to nontreatment controls.48
The difference observed in this trial likely stems from the
method of infection used. In antibiotic drop efficacy studies,
corneal infection generally are achieved using an intrastromal
injection of the offending organism. In contrast, in the current
study infection was preceded by a corneal scratch and break in
the corneal epithelium. This break in the epithelium can
provide an avenue for the antibiotic to reach the microorgan-
isms, while in intrastromal injection models, the antibiotic
must traverse through the significant intact epithelial barrier.
The performance of the unmodified control lenses in
comparison with the treatment with eye drops is illustrative
of the dosing needed to eradicate the bacterial organisms. Eye
drop therapy was able to sterilize the corneas, but only after
repeated instillations over time to ensure that an adequate
amount of the antibiotic reaches the ocular structures. Based
on its in vitro release kinetics, the control lenses release
ciprofloxacin as a very quick initial burst, and any of the drug
that is not absorbed is presumably lost. In this manner, the
dosing provided by application of a ciprofloxacin-loaded,
unmodified control lens behaves much like a single eye drop
instillation. Thus, for the control lens to be effective in
eradicating bacterial growth, the application of the CL would
need to follow the schedule seen with eye drops. Repeated
removal of worn lenses and replacement with loaded lenses
would have been necessary to provide the proper dose,
negating any practical advantages of the drug delivery system.
Recently, there has been a report by a research group
demonstrating the feasibility of an extended antibiotic-releas-
ing CL for the prevention of ocular infections.49 In their model
of bacterial endophthalmitis, infection was achieved through
anterior chamber injection of a methicillin-resistant strain of
Staphylococcus aureus.49 Untreated, after 24 hours approxi-
mately 105 CFU/mL of bacteria were recovered from the
experimental eyes, while treatment with topical fluoroquino-
lone eye drops only reduced the number of recovered bacteria
to approximately 104 CFU/mL. In contrast, immediate treat-
ment after bacterial injection with their experimental gatiflox-
acin-releasing CLs completely prevented growth of
microorganisms, proving the utility of their lenses in poten-
tially preventing postoperative infections of the globe. The
results of the current study extend the application of antibiotic-
releasing CLs even further, with the aim of treatment of
infection rather than mere prevention. Delay in treatment of
the exposed animals with CLs or eye drops allows for the
clinical signs and symptoms of an infection to occur, framing
the results from these trials in the context of treatment of
ocular infections rather than prevention.
In conclusion, in this study, the development of a slow
release ciprofloxacin CL system was achieved using a
molecular imprinting strategy. Evaluations in vitro show the
potential of these materials to release clinically relevant
amounts of the antibiotic while retaining critically important
CL material properties, and evidence from in vivo testing show
that they can perform similarly to antibiotic drop therapy in
models of MK. Application of these materials may be useful for
future treatment paradigms of MK.
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